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ABSTRACT We have examined the role played by protein
kinase A (PKA) in vesicle-mediated protein transport from the
trans-Golgi network (TGN) to the cell surface. In vivo this
transport step was inhibited by inhibitors of PKA catalytic
subunits (C-PKA) such as the compound known as H89 and a
myristoylated form of the inhibitory peptide sequence contained
in the thermostable PKA inhibitor. Inhibition by H89 occurred
at an early stage during the transfer of vesicular stomatitis virus
G glycoprotein from the TGN to the cell surface. Reversal from
this inhibition correlated with a transient increase in the number
of free coated vesicles in the Golgi area. Vesicle budding from the
TGN was studied in vitro using vesicular stomatitis virus-
infected, permeabilized cells. Addition to this assay of C-PKA
stimulated vesicle release while it was suppressed by PKA
inhibitory peptide, H89, and antibody against C-PKA. Further-
more, vesicle release was decreased when PKA-depleted cytosol
was used and restored by addition of C-PKA. These results
indicate a regulatory role for PKA activity in the production of
constitutive transport vesicles from the TGN.
Transport of newly synthesized proteins along the exocytic path-
way is mediated by small vesicular carriers (1, 2). A set of proteins
collectively known as the transport machinery is responsible for
the formation and consumption of vesicles. These include recep-
tor proteins that sort and concentrate cargo molecules at the
budding site, coat proteins that catalyze budding from the donor
compartment, and proteins responsible for targeting and fusion
with the acceptor membrane (1). Recent evidences indicate that
the transport machinery is regulated by specific phosphorylating
activities that in this way modulate intracellular traffic. Thus,
phosphatidylinositol-3 kinase has been shown to be required for
transfer of hydrolases from the Golgi to either the yeast vacuole
(3) or the mammalian lysosomes (4, 5). Release of secretory
vesicles from the trans-Golgi network (TGN) of endocrine cells
has also been shown to be regulated by tyrosine phosphorylation
(6). Both protein kinase A (PKA) and protein kinase C (PKC)
activities have been reported to control particular vesicle-
mediated transport steps such as constitutive (7–11) and regu-
lated exocytosis (12–15) and transcytosis (16, 17). Whereas the
effects derived from the activationyinhibition of these different
kinases on transport are well documented little information is
available about their mechanism of action. PKC activity has been
described to stimulate association of ADP ribosylation factor and
coatomer proteins to Golgi membranes (18) but recent data
indicate that its phosphorylating activity is not required for vesicle
budding from the TGN (19). Therefore, it is uncertain at present
in which way protein kinases control transport activities. We have
recently described that PKA differentially regulates constitutive
protein transport along the exocytic pathway with transport from
the TGN to the cell surface being strictly dependent on PKA
activity (20). We now have extended these studies to the char-
acterization of the site of action of PKA. The results indicate that
vesicle budding from the TGN requires PKA activity.
MATERIALS AND METHODS
Materials. Bovine brain cytosol was prepared as described (21)
and dialyzed extensively against 25 mM TriszHCl, pH 8.0, 50 mM
KCl, and 1 mM DTT. The preparation was centrifuged for 1 h at
100,000 3 g (SW60 rotor, Beckman Instruments) to remove
aggregates; aliquots were frozen and maintained at 270°C.
Before being used cytosolic proteins were transferred to 25 mM
Hepes-KOH, pH 7.0, containing 25 mM KCl, 2.5 mM MgCl2 by
application to a Econo-PacI0DG Bio-Rad column. To deplete
PKA, 0.5 ml cytosol ('4 mgyml) was incubated with cAMP-
agarose (Sigma) for 1 h at 4°C, packed into a 2.5 ml column and
the flow-through fraction collected. The following antibodies
were used: 8G5F11 (clone I1) monoclonal antibody against the
extracytoplasmic domain of vesicular stomatitis virus G glyco-
protein (VSV-G) (22) was kindly provided by D. S. Lyles (Wake
Forest University, NC); P5D4 mAb against the C terminus of
VSV-G (23) was purchased from Sigma; rabbit polyclonal IgG
against PKA catalytic subunit (C-PKA) was obtained from Santa
Cruz Biotechnology; and antisera recognizing TGN38 (24) and
a-1,2-mannosidase II (25) were obtained from G. Banting (Uni-
versity of Bristol, Bristol, U.K.) and M. G. Farquhar (University
of California, San Diego), respectively. C-PKA, PKA inhibitory
peptide (PKI), apyrase, neuraminidase, protein G-Sepharose
were purchased from Sigma. Myristoyl-PKI was from Quality
Control Biochemicals (Hopkinton, MA), N-[2-(-p-bromocin-
namylamino)ethyl]-5-isoquinolinesulfonamide (H89) from Cal-
biochem, and endoglycosidase H and proteinase K from Boehr-
inger Mannheim.
Cell Culture and Virus Infection. Normal rat kidney cells
were maintained in monolayer culture in DMEM containing
10% (volyvol) fetal calf serum, 2 mM L-glutamine, 50 unitsyml
penicillin, and 50 mgyml streptomycin. Confluent cultures
were infected at 37°C with VSV at a multiplicity of 25–30
plaque-forming units per cell in serum-free medium for 45 min
(26). Cells were incubated in complete medium for 3 h before
start the experiments.
Metabolic Labeling and VSV-G Immunoprecipitation. Cells
cultured on 35-mm dishes were used. They were incubated at
37°C in methionine- and cysteine-free medium for 15 min and
radiolabeled for 5 min with 25 mCi Tran35S-label (1 Ci 5 37
GBq). Cells were rinsed and chased at 20°C in complete
medium containing 1.5 mgyml of both unlabeled methionine
and cysteine. Immunoprecipitation of VSV-G from the cell
surface was performed with 8G5F11 antibody as described
(20). Intracellular VSV-G was immunoprecipitated with P5D4
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antibody (20). Immunocomplexes were purified with protein
G-Sepharose and analyzed by SDSyPAGE.
Vesicle Release Assay from Permeabilized Cells. The assay
described by Mu¨sch et al. (27) was used with few modifications.
Cells cultured on 100-mm dishes were infected, radiolabeled for
10 min with 200 mCi Tran35S-label, and chased at 20°C for 2 h.
They were permeabilized according to the swelling technique
described by Beckers et al. (28). Permeabilized cells were incu-
bated on ice for 10 min with high salt buffer (20 mM Hepes-KOH,
pH 7.2y500 mM potassium acetatey2 mM magnesium acetatey1
mM DTT), and resuspended in transport buffer (20 mM Hepes-
KOH, pH 7.2y90 mM potassium acetatey2 mM magnesium
acetatey1 mM DTT). The standard incubation mixture con-
tained: permeabilized cells (25–30 mg of protein), 50 mg bovine
brain cytosol, 1 mM GTP, and ATP-generating system (1 mM
ATPy5 mM creatine phosphatey0.2 unitsyml of creatine phos-
phokinase) in a final volume of 50 ml. In experiments involving
treatment with either glycosidases, proteinase K or immunode-
tection of Golgi integral proteins the assay was scaled up 3–5-fold.
Incubation took place at 37°C for 2 h after which the cells were
pelleted at 800 3 g for 5 min. Unless indicated otherwise both
fractions, pellet and supernatant, were solubilized with 1% (voly
vol) Triton X-100 and subjected to immunoprecipitation of
VSV-G and SDSyPAGE analysis. Vesicle formation was evalu-
ated by the amount of VSV-G released from cells and expressed
as the percentage of the total labeled protein initially present in
the cells that appeared in the supernatant. In some experiments,
immunoprecipitated VSV-G was digested overnight at 37°C with
2 milliunits of either endoglycosidase H or neuraminidase prior
to SDSyPAGE (20).
Electrophoresis and Western Blot Analysis. Reduced proteins
were separated on 7.5% SDSyPAGE. 35S-labeled proteins were
quantitated in a PhosphorImager (FUJIX Bas 1000, Tokyo) using
the PC-BAS, 2.08, program. Protein samples to be analyzed by
Western blot analysis were transferred to Immobilon-P (Milli-
pore). Blots were incubated with the appropriate primary anti-
body followed by horseradish peroxidase-conjugated secondary
antibody (Amersham). They were developed using the enhanced
chemiluminescence detection system (Amersham) and quanti-
tated by scanning densitometry.
Electron Microscopy. Cells were cultured on 35-mm dishes and
processed as described (20). To estimate the density of coated
vesicles in the Golgi area 6–10 consecutive, serial sections from
5–7 different cells were analyzed for each experimental condition.
The Golgi area was defined as the cytoplasmic region that contains
the Golgi stack and its immediate surroundings including adja-
cent vesicles and transitional elements of the endoplasmic retic-
ulum, but excluding most of the other organelles such as mito-
chondria, large endosomes, and endoplasmic reticulum cisternae.
For each section a photograph was taken at a final magnification
of 326,700 and the surface of the Golgi area was determined
using an electronic pen connected to a microprocessor pro-
grammed (VIDEOPLAN 2.5) to calculate surface area. The volume
of each Golgi area was determined by multiplying the mean
surface by the thickness of the section ('70 nm) and the number
of individual sections included in the analysis. Free-coated vesi-
cles with a diameter ,70 nm were counted on each section.
RESULTS
Inhibitors of PKA Activity Block Transport of VSV-G
Glycoprotein from the TGN to the Cell Surface. To assess the
influence of PKA activity on vesicle-mediated protein trans-
FIG. 1. Effect of myristoyl-PKI on transport of VSV-G from the
TGN to the cell surface. VSV-infected, normal rat kidney cells were
radiolabeled with Tran35S-label at 37°C for 5 min and chased at 20°C
for 2 h to accumulate newly synthesized VSV-G in the TGN. They were
either incubated on ice or, alternatively, exposed to myristoyl-PKI at
20°C for 45 min. Cells were transferred to 37°C and additionally
incubated at this temperature for 40 min. (A) VSV-G was immuno-
precipitated from the cell surface and analyzed by SDSyPAGE. Total
VSV-G present within the cells is shown. (B) The amount of VSV-G
reaching the cell surface was calculated. Values were normalized for
the total amount of VSV-G glycoprotein present in the cells and
expressed as percentage of VSV-G transported in untreated, control
cells. Data (mean 6 SD) are average of three different experiments.
FIG. 2. Time course of H89 inhibition of transport of VSV-G from
the TGN to the cell surface. Infected, radiolabeled cells were incu-
bated at 20°C for 2 h. They were then transferred to 37°C to allow
radiolabeled VSV-G retained in the TGN to be transported to the cell
surface. Transport was arrested at the indicated time points; cells were
transferred on ice and incubated or not (control) with 50 mM of H89
for 30 min. In the case of H89-treated cells, transport was reestablished
by returning the cells to 37°C to complete a 40 min transport period
in the continuous presence of this agent. VSV-G was immunoprecipi-
tated from the cell surface and subjected to SDSyPAGE analysis. (A)
Access to the cell surface of VSV-G is compared in untreated, control
cells and cells incubated with H89. (B) The amount of VSV-G reaching
the cell surface is expressed as percentage of that in control cells.
Values were normalized for the total amount of VSV-G within the
cells. They are representative of three independent experiments.
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port processes we examined the effects derived from incubat-
ing intact cells with selective PKA inhibitors. A lipid derivative
of PKI, the inhibitory peptide sequence of the heat-stable PKA
inhibitor, was first used. The heat-stable PKA inhibitor is a
natural, highly specific inhibitor of C-PKA (29). VSV-infected
cells were radiolabeled and incubated at 20°C to accumulate
newly synthesized VSV-G in the TGN (30). Transport to the
cell surface of this integral membrane glycoprotein was rees-
tablished by shifting the cells to 37°C and analyzed in the
presence of increasing concentrations of myristoyl-PKI. Ra-
diolabeled VSV-G was immunoprecipitated from the cell
surface and evaluated by SDSyPAGE. Transport was de-
creased in cells treated with myristoyl-PKI (Fig. 1A). This
inhibition was not complete, however; 40–45% of newly
synthesized VSV-G molecules still reached the cell surface
during 40 min transport. During the same period of time .65%
of the VSV-G molecules were detected at the cell surface in
control, untreated cells. Maximal inhibition occurred with
10–20 mM myristoyl-PKI; no further inhibition was obtained at
higher concentrations (Fig. 1B). In contrast, transport from the
TGN to the cell surface was strongly inhibited in the contin-
uous presence of H89 (Fig. 2A, lane 0 of samples treated with
H89), a cell permeable inhibitor of C-PKA (31). Used at 35–50
mM this isoquinolinesulfonamide derivative blocked transfer
of VSV-G from the TGN to the cell surface. This corroborates
previous results with this reagent (20). In addition, it suggests
an inefficient inhibition of cellular C-PKA by myristoyl-PKI.
Most likely, the latter inhibitor became anchored to the cell
membrane and this should have hindered interaction with
soluble C-PKA. Nevertheless, transport inhibition observed
with myristoyl-PKI clearly established the involvement of PKA
activity in vesicle traffic between the TGN and the plasma
membrane. These data extend previous studies on the effects
of PKA activators on the same transport route (7, 9, 20).
H89 Inhibits Vesicle Budding from the TGN in Vivo. To
determine the site of action of PKA in the transport process we
analyzed the time at which H89 was effective as inhibitor. Cells
containing radiolabeled VSV-G accumulated in the TGN at 20°C
were shifted to 37°C and H89 was added at different time points
during the transfer of this glycoprotein to the cell surface (Fig. 2).
Effective transport inhibition was obtained when H89 was added
during the first 5–10 min of transport (Fig. 2B). Addition of H89
at later time points did not significantly affected VSV-G access to
the cell surface. This suggested a primary role for PKA in protein
export from the TGN rather than vesicle targeting and fusion with
the plasma membrane. To support this view we carried out a
morphological experiment designed to examine structural
changes in the Golgi area during reversal from a H89 block. Cells
were maintained at 20°C for 2 h and exposed to H89 during the
last 30 min of incubation at this temperature. They were then
additionally incubated at 37°C in the continuous presence of H89
for 30 min. This should allow proteins retained in the TGN by the
temperature block to gain access to the cell surface. Finally, H89
was washed out and the cells were processed for electron micros-
copy at different time points during reversal. The Golgi region
showed an increase in the number of free-coated vesicles follow-
ing H89 removal (Fig. 3). While coated buds and vesicles were
observed in the presence of H89 (Fig. 3A) the latter increased
significantly after incubation in H89-free medium for 5–8 min
(Fig. 3B). Apparently, as much as twice vesicles were detected
under these conditions (Fig. 3C). They were identified as trans-
port vesicles by immunogold detection of VSV-G (not shown). At
later time points the number of free vesicles in the Golgi area
decreased as they probably reached the plasma membrane (not
shown). Taken together these data indicated that PKA activity
was necessary at an early stage of vesicle production in the
constitutive transport of VSV-G from the TGN to the cell
surface.
Effects of PKA Activity on Vesicle Release from the TGN. To
demonstrate the involvement of PKA activity on vesicle for-
mation we used an in vitro assay previously described to
reproduce this transport stage (27). Infected, radiolabeled cells
were incubated at 20°C to accumulate VSV-G at the TGN.
They were osmotically permeabilized (28), depleted from
endogenous cytosolic components, and incubated at 37°C in
the presence of exogenous cytosol, GTP, and ATP-generating
system. Released vesicles were separated from permeabilized
cells by low speed centrifugation, lysed, and subjected to
SDSyPAGE analysis after VSV-G immunoprecipitation (Fig.
4). Vesicle budding in this assay accounted for the release of
'20–30% of the total radiolabeled VSV-G initially present
within the cells. It occurred in a temperature and cytosol-
dependent manner since almost no VSV-G was released from
permeabilized cells maintained at either 4°C or 20°C or
FIG. 3. Ultrastructural changes in the Golgi region during reversal from a H89 block. Cells were incubated at 20°C for 2 h. 50 mM H89 was
added during the last 30 min of incubation at this temperature. They were transferred to 37°C and additionally incubated with H89 for 30 min.
(A) Cells were directly fixed and processed for electron microscopy. (B) Alternatively, they were additionally incubated in H89-free medium for
8 min prior to fixation. Vesicles and buds located at the trans Golgi face are indicated with arrowheads and arrows, respectively. (C) Number of
free coated vesicles in the Golgi area determined as described in Materials and Methods. Data (mean 6 SD) are the average of at least five different
Golgi areas. (Bars 5 0.25 mm.)
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incubated in the absence of exogenous cytosol (Fig. 4A).
Importantly, vesicle budding required ATP hydrolysis. Addi-
tion of apyrase to the assay inhibited VSV-G release and this
could not be explained by lack of GTP since apyrase inhibition
was also effective in the presence of the nonhydrolyzable GTP
analog, GTPgS (Fig. 4B). Released VSV-G was terminally
glycosylated as indicated by resistance to endoglycosidase H
and sensitivity to neuraminidase digestion (Fig. 4C). In addi-
tion, experiments with proteinase K revealed that released
VSV-G was contained in intact vesicles (Fig. 4D). Treatment
of the vesicle fraction with this protease did not render
complete degradation of VSV-G unless Triton X-100 was
included. Instead, released VSV-G exposed to proteinase K in
the absence of detergent underwent a small increase in its
electrophoretic mobility that was probably the result of partial
proteolysis affecting its cytoplasmic tail (Fig. 4D). Taken
together these data indicated that released VSV-G molecules
were confined into sealed vesicles that were for the most part
TGN-derived. Integral Golgi proteins such as a-1,2-
mannosidase II (25) and TGN38 (24) remained concentrated
in the cell pellet after vesicle release (Fig. 4E). In the case of
TGN38 a small amount (,5%) was released consistent with
the recycling of this protein between the TGN and the plasma
membrane (32). These data exclude the possibility of general
Golgi vesiculation during the in vitro incubation. We therefore
used this assay to evaluate the influence of PKA activity on
vesicle formation. As shown in Fig. 5 addition of pure C-PKA
subunits to the incubation medium stimulated vesicle release
by 2-fold. At least 35% of total VSV-G present within the cells
was released into vesicles under C-PKA stimulation. Such
stimulation was both cytosol and ATP-dependent and the
extra amount of VSV-G released in the presence of C-PKA was
sensitive to neuraminidase digestion (Fig. 5B). This indicated
that exogenous C-PKA indeed stimulated vesicle budding from
the TGN. Functional C-PKA subunits were required because
no stimulation occurred when heat-inactivated C-PKA were
used (Fig. 5C). Moreover, addition of PKI to the standard
assay inhibited vesicle formation (Fig. 5A). This synthetic
peptide drastically decreased vesicle release. Whereas .50%
inhibition was observed at low concentrations such as 5–10
mM, maximal inhibition (80–90%) required 20–30 mM (Fig.
5D). Addition to the assay of an unrelated peptide only
marginally affected vesicle release (,20% inhibition at 35–50
mM). Vesicle production was also inhibited by H89 (Fig. 5D).
In this case, 85% inhibition occurred at 5–10 mM, that is
7–10-fold lower than the concentration of this agent needed to
inhibit transport in vivo. Vesicle generation from the TGN was
abolished by addition to the incubation medium of a specific
FIG. 4. Release of post-Golgi vesicles from permeabilized cells. The standard assay consisted of permeabilized cells containing radiolabeled
VSV-G accumulated in the TGN, exogenous cytosol, GTP, and ATP-generating system (see Materials and Methods). Incubation took place at 37°C
for 2 h. The vesicle fraction (V) was separated from the permeabilized cells (P) by centrifugation and its content in VSV-G determined by
immunoprecipitation and SDSyPAGE analysis. (A) Comparison of the amount of VSV-G released into vesicles (V) vs. that remaining within the
cells (P) in control conditions. VSV-G released in incubations lacking exogenous cytosol (2cytosol) or performed at low temperature (20°C) is
shown. (B) ATP requirement: incubation was carried out in the presence of 1 mM GTPgS instead of GTP and additionally with or without (control)
0.6 unitsyml apyrase. (C) Glycosylation of released VSV-G: VSV-G immunoprecipitated from vesicles was subjected or not (nondigested, nd) to
either endoglycosidase H (endo H) or neuraminidase (neu) digestion before SDSyPAGE. (D) Vesicle integrity: released vesicles were incubated
or not (nd) on ice for 30 min with 0.5 mgyml proteinase K (K) in the presence or absence of 1% (volyvol) Triton X-100 (TX100). VSV-G was then
immunoprecipitated with 8G5F11 antibody against its extracytoplasmic domain. (E) Detection of both a-1,2-mannosidase II (Man II) and TGN38:
30 mg of membrane proteins from both fractions (P, V) were resolved by SDSyPAGE and determined by Western blot analysis.
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antibody against C-PKA whereas no effect was observed with
preimmune IgG (Fig. 5A). Finally, we examined the effect of
using a cytosol preparation with low PKA activity. More than
70% of C-PKA protein was extracted following incubation of
native cytosol with cAMP-agarose (Fig. 6A). Vesicle genera-
tion was 45% decreased in incubations with this depleted
cytosol. After addition of C-PKA the ability of this cytosol
preparation to support vesicle budding was restored to 95% of
that in control conditions (Fig. 6B). Taken together these
results indicated that formation of constitutive transport ves-
icles at the TGN is modulated by PKA activity.
DISCUSSION
In a previous report we have described that transport of newly
synthesized VSV-G along the secretory pathway was arrested
in cells treated with H89, a specific PKA inhibitor (20).
Whereas both endoplasmic reticulum-to-Golgi and intra-Golgi
transport steps were sensitive to H89 treatment this agent
mostly blocked export out of the Golgi complex to the cell
surface. These results contrast with data published by Simon
et al. on the production of post-Golgi vesicles from purified
Golgi fractions (10). In this study vesicle release was only
50–60% inhibited by H89 while it was sensitive to PKC
inhibitors and activators. Moreover, a novel PKC isoform,
named PKCm, has been recently described to be located in the
Golgi complex and inhibited by H89 (33). It was, therefore,
important that in the present study we establish the involve-
ment of PKA activity in transport from the TGN to the cell
surface. The results obtained with myristoyl-PKI indicate that
this is indeed the case. This synthetic peptide contains the
inhibitory sequence of the thermostable PKA inhibitor, a
FIG. 6. Effects of C-PKA depletion from cytosol on vesicle release.
(A) 45 mg of cytosolic proteins from both native bovine brain cytosol
(control) and cytosol incubated with cAMP-agarose (depleted) were
processed by SDSyPAGE and their content in C-PKA determined by
Western blot analysis. (B) The vesicle release assay was performed in the
presence of either native cytosol (control), C-PKA-depleted cytosol
(depleted), or C-PKA-depleted cytosol supplemented with 8 units C-
PKA. VSV-G immunoprecipitated from released, lysed vesicles is shown.
FIG. 5. Effects of PKA modulators on vesicle release from the TGN. (A) The standard assay described in Fig. 4 was supplemented or not (control)
with either 8 units C-PKA, 20 mM PKI, 2 mg anti-C-PKA antibody or 2 mg preimmune rabbit IgG. (B) Incubation was performed in the presence
of 8 units C-PKA but in the absence of either ATP (1apyrase) or cytosol (2cytosol) or in complete medium (control). VSV-G was
immunoprecipitated from released, lysed vesicles, and where indicated (neu) subjected to neuraminidase digestion prior to SDSyPAGE analysis.
(C) Effect of adding different amounts of both native (E) and heat-inactivated (90°C, 30 min) (F) C-PKA subunits on vesicle release. (D) Effect
of adding different amounts of either PKI (E) or H89 (F) on vesicle release. Data are the average of three independent experiments.
Cell Biology: Mun˜iz et al. Proc. Natl. Acad. Sci. USA 94 (1997) 14465
protein that specifically inhibits PKA activity and has no effect
on other kinase families (29). Although transport of VSV-G
from the TGN to the cell surface was not completely blocked
in cells incubated with myristoyl-PKI it was significantly de-
creased (Fig. 1). It is reasonable to assume that the inhibitory
efficacy of this reagent was limited by its access to the cell
interior. It has also been shown that PKI peptide is 10-fold less
efficacious than the full-length inhibitor (29). Additionally,
inhibition of other kinases in addition to PKA by H89 cannot
be excluded at present. Nevertheless, a regulatory role for PKA
activity in the TGN-to-cell surface transport is supported by
data obtained with activators such as 3-isobutyl-1-methylxan-
thine and forskolin (7, 9, 20).
Both biochemical (Fig. 2) and morphological (Fig. 3) data
obtained in cells treated with H89 indicate that this inhibitor
prevents the formation of constitutive transport vesicles from the
TGN. In control, untreated cells transfer of VSV-G to the cell
surface from the TGN occurs after a 10 min lag (20). This time
period seems to be required for coat assembly and vesicle
formation. Transport inhibition by H89 occurred during this stage
suggesting that PKA activity is necessary to generate the vesicular
carriers that mediate transport from the Golgi to the cell surface.
In contrast, a role for PKA activity on vesicle targeting andyor
fusion seems to be excluded from the absence of H89 inhibitory
effect at later time points. Removal of H89 block gave rise to a
transient increase in the number of free coated vesicles in the
Golgi area. While most of these vesicular profiles were seen
associated to TGN elements some of them were located close to
the endoplasmic reticulum and proximal Golgi cisternae. It is thus
possible that PKA activity affects vesicle formation at more than
one location in the secretory pathway.
By using an in vitro assay that reproduces vesicle budding from
the TGN (Fig. 4) we have been able to directly test the influence
of PKA activity on this process. Vesicle production was stimulated
by exogenous C-PKA (Fig. 5) while it was inhibited by depletion
of endogenous C-PKA (Fig. 6). Interestingly, the stimulatory
effect caused by C-PKA on vesicle budding in vitro roughly
matches the increase in the number of free vesicles observed in
vivo during H89 reversal. Therefore, data obtained from both in
vivo and in vitro systems correlate well and indicate that PKA
activity is necessary to generate transport vesicles from the TGN.
The inhibitory efficacy of both H89 and PKI was higher in the in
vitro assay than in vivo. However, the concentrations of both
inhibitors needed to inhibit vesicle release were still far above
their Ki for PKA ('0.08 nM for PKI and 50 nM for H89) (29, 31).
In the case of H89 high concentrations (10–50 mM) of this reagent
were also used in previous studies to inhibit transport activities
(10, 17, 34). It is therefore possible that the interaction in situ of
both inhibitors with C-PKA depends on factors such as the
particular isoenzyme involved or membrane localization which
are unclear at present.
Vesicle budding depends on the assembly of a protein coat
that is recruited on the cytosolic side of donor membrane from
soluble components (2, 35). The coat is thought to act as a
mechanical device that drives membrane deformation into a
bud. Several coat proteins (36–39) and proteins that activate
coat assembly (40–42) contain PKA phosphorylation se-
quences. It is therefore possible that PKA activity determines
vesicle budding by regulating the interaction of particular sets
of coat proteins with intracellular membranes. In addition, or
alternatively, PKA could have a role in cargo selection and
packaging at the TGN.
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